



1 Physiology and pathophysiology of excitation–contraction 2 coupling in skeletal muscle: the functional role of ryanodine 3 receptor

4 Gaetano Santulli^{1,2}  · Daniel Lewis^{1,2} · Andrew R. Marks^{1,2,3}

5 Received: 7 February 2017 / Accepted: 6 April 2017
6 © Springer International Publishing Switzerland 2017

7 **Abstract** Calcium (Ca^{2+}) release from intracellular stores
8 plays a key role in the regulation of skeletal muscle con-
9 traction. The type 1 ryanodine receptors (RyR1) is the
10 major Ca^{2+} release channel on the sarcoplasmic reticu-
11 lum (SR) of myocytes in skeletal muscle and is required
12 for excitation–contraction (E–C) coupling. This article
13 explores the role of RyR1 in the skeletal muscle physiology
14 and pathophysiology.

15 **Keywords** Calcium · Excitation–contraction coupling ·
16 Muscular dystrophy · RyR1 · Skeletal muscle

17 Introduction

18 Ryanodine receptors (RyRs) are intracellular calcium
19 (Ca^{2+}) release channels located on the endo/sarcoplasmic
20 reticulum (ER/SR) (Flucher et al. 1993), a heterogene-
21 ous intracellular compartment consisting of a network of
22 tubules (Chen et al. 2013; Brochet et al. 2005) represent-
23 ing the major Ca^{2+} reservoir within the cell. There are three
24 subtypes of RyRs in mammalian tissues: RyR1 and RyR2
25 are required for skeletal muscle and cardiac excitation–
26 contraction coupling (E–C coupling), respectively (Marks et al.

1989; Otsu et al. 1990), and are also expressed in non-
27 muscle tissues (Awad et al. 1997); RyR3, originally iden-
28 tified in the brain (Nakashima et al. 1997), is also widely
29 expressed (Zhang et al. 2011).
30

31 RyR1 facilitates the rapid and coordinated release of
32 Ca^{2+} from SR stores to activate skeletal muscle contrac-
33 tion. EC coupling is the process that converts electrical sig-
34 nals and rising Ca^{2+} levels into mechanical output (muscle
35 contraction). RyRs are highly regulated for precise control
36 and Ca^{2+} plays the key signaling role in activating the chan-
37 nel and amplifying the signal (Endo et al. 1970). In this
38 process, depolarization of the plasma membrane activates
39 L-type voltage-gated calcium channels (Ca_v), which signal
40 RyRs located on the SR to gate open and release Ca^{2+} to
41 activate muscle contraction (Rios and Brum 1987; Gor-
42 don et al. 2000; Tobacman 1996; des Georges et al. 2016).
43 RyR is a 2.2 mega Dalton homotetramer, composed of four
44 ~5000 residue protomers (Marks et al. 1989; Santulli and
45 Marks 2015), making it the largest known ion channel (des
46 Georges et al. 2016; Santulli and Marks 2015; Zalk et al.
47 2015). The narrow transmembrane core and larger cyto-
48 plasmic shell result in a mushroom shaped structure (des
49 Georges et al. 2016; Zalk et al. 2015; Hwang et al. 2012).
50 The large shell interacts with other receptors and forms
51 much of the regulatory mechanism for the channel, allow-
52 ing a range of stimuli to exert precise control over opening
53 (Marks et al. 1989; des Georges et al. 2016; Santulli and
54 Marks 2015; Zalk et al. 2015; Brillantes et al. 1994; Marx
55 et al. 1998, 2000; Marks 2003; Reiken et al. 2003; Lehnart
56 et al. 2005; Huang et al. 2006; Bellinger et al. 2009; Kush-
57 nir et al. 2010; Shan et al. 2010; Andersson et al. 2011;
58 Lanner et al. 2010). The core of RyR houses the approxi-
59 mately 90 Å long pore responsible for passage of Ca^{2+} from
60 the ER/SR to the cytoplasm (des Georges et al. 2016; Yan
61 et al. 2015). This cation channel is actually poorly selective

A1 ✉ Gaetano Santulli
A2 gsantulli001@gmail.com

A3 ¹ The Wu Center for Molecular Cardiology, Columbia
A4 University, New York, NY, USA

A5 ² Department of Physiology and Cellular Biophysics, College
A6 of Physicians and Surgeons, Columbia University Medical
A7 Center, Columbia University, New York, NY, USA

A8 ³ Department of Medicine, Columbia University, New York,
A9 NY, USA

62 for Ca^{2+} (~7-fold selective for Ca^{2+} vs K^{+}) and displays an
 63 exceptionally large single channel conductance (Santulli
 64 and Marks 2015).

65 We recently solved the high-resolution structure of
 66 RyR1 using cryogenic electron microscopy (cryo-EM) (des
 67 Georges et al. 2016; Zalk et al. 2015), confirming that it
 68 adopts a fourfold symmetric mushroom-like superstructure,
 69 with the large ‘cap’ (about 80% of the mass) located in the
 70 cytosol and the ‘stalk’ embedded in the ER/SR membrane,
 71 with six transmembrane helices (S1–S6) per protomer sur-
 72 rounding the central pore (des Georges et al. 2016). Each
 73 protomer is built around an extended scaffold of alpha-solenoid
 74 repeats which include an aminoterminal, a bridging,
 75 and a core solenoid (des Georges et al. 2016; Zalk et al.
 76 2015). At the extreme outer corners of the tetramer there
 77 are three SPRY domains and two pairs of RyR repeats,
 78 RY12 and RY34, the latter containing a regulatory protein
 79 kinase A (PKA) phosphorylation site (Marx et al. 2000).
 80 The RyR1 pore domain most closely resembles that of the
 81 voltage-gated sodium channel (NavAB) and presents a single
 82 cytosolic constriction in the ion conduction pathway, at
 83 the S6 bundle crossing (Zalk et al. 2015). Glycine residues

84 in the pore-lining helices may operate as “hinges” to facili-
 85 tate the orientation of the cytoplasmic extension of S6 in
 86 order to modulate the aperture of the channel. In particular,
 87 Gly^{4934} is conserved in all RyR isoforms and in the IP3R.

RyR macromolecular complex

88
 89 The ER/SR of most cell types contains two types of
 90 intracellular Ca^{2+} release channels: the ryanodine recep-
 91 tors (RyRs) and the inositol 1,4,5-trisphosphate recep-
 92 tors (IP3Rs) (Santulli and Marks 2015; Go et al. 1995;
 93 Yuan et al. 2016; Santulli 2017). There is ~40% homol-
 94 ogy between the RyR and IP3R in the putative transmem-
 95 brane regions (Marks et al. 1989, 1990; Santulli 2017), a
 96 sequence similarity sufficient to indicate that these two
 97 channels evolved from a common ancestral cation release
 98 channel in unicellular species. The structural homology
 99 between RyR1 and IP3R1 is depicted in Fig. 1.

100 RyR was named based on its purification using the high
 101 affinity plant alkaloid ryanodine (Rogers et al. 1948), an
 102 agent known to profoundly alter intracellular Ca^{2+} handling
 103 (Fairhurst and Hasselbach 1970). Indeed, when bound to




Fig. 1 Structural homology between the intracellular Ca^{2+} release channels IP3R1 (*top*) and RyR1 (*bottom*). In **a**, **c** channels are viewed from the ER/SR lumen; in **c**, *arrowheads* indicate Calstabin

RyR at low concentrations ryanodine locks the channel in a half open state, thereby resulting in depletion of Ca^{2+} from the SR and subsequent interruption of E–C coupling. This explains the historical use of extracts from the *Ryania* plant family by natives of South and Central America as poison for blow darts: the release of SR Ca^{2+} via the locked open RyRs causes tetany, and at high concentrations ryanodine blocks the channel (Rogers et al. 1948). RyR is normally closed at low cytosolic $[\text{Ca}^{2+}]$ (~100–200 nM); at sub-micromolar cytosolic $[\text{Ca}^{2+}]$ Ca^{2+} binds to high-affinity binding sites on RyR increasing the open probability (P_o) of the channel (Bezprozvanny et al. 1993). Channel activity is maximal at cytosolic $[\text{Ca}^{2+}]$ ~10 μM while elevating cytosolic $[\text{Ca}^{2+}]$ beyond this point leads to a reduction in P_o (Bezprozvanny et al. 1993; Copello et al. 1997; Laver et al. 1995).

The large and complex structure of RyR contains function-modifying phosphorylation sites and protein-binding domains, providing an attractive target for disease intervention (des Georges et al. 2016; Santulli and Marks 2015; Zalk et al. 2015; Brillantes et al. 1994; Marx et al. 1998, 2000, 2001; Marks 2003; Lehnart et al. 2005; Kushnir et al. 2010; Marks et al. 2002). RyRs are macromolecular signaling complexes, in which multiple proteins bind to a domain of the channel modulating its function (Marks et al. 1989, 2002). The Ca^{2+} stabilizing proteins calstabin1 (Calcium channel stabilizing binding protein, previously known as FKBP12) and calstabin2 (FKBP12.6) are peptidyl-propyl-*cis-trans* isomerases that associate via amphiphilic β -sheet structures with RyR1 and RyR2, respectively, such that one calstabin protein is bound to each RyR monomer (des Georges et al. 2016; Zalk et al. 2015; Jayaraman et al. 1992; Timerman et al. 1993; Xin et al. 1995; Yuan et al. 2014), in order to modulate the channel gating through protein–protein interactions (Brillantes et al. 1994) and prevent pathological intracellular Ca^{2+} leak that cause diseases (Marks 2003; Huang et al. 2006). Calstabin1 and calstabin2 differ at only 18 positions out of 108 residues. We identified the calstabin-binding loop as part of the aminoterminal subdomain of the bridging solenoid (Zalk et al. 2015). Calstabin binding may rigidify the interface between such a subdomain with SPRY1–2, thereby stabilizing the connection with the cytosolic regulatory domains and eventually altering the relative orientation of these domains (Zalk et al. 2015). Highly conserved leucine–isoleucine zipper motifs in RyR2 form binding sites for adaptor proteins that mediate binding of other proteins (Marx et al. 2001; Marks et al. 2002), including kinases (e.g. PKA) (Reiken et al. 2003; Shan et al. 2010) CaMKII δ (Kushnir et al. 2010) and phosphatases (e.g. PP1 and PP2A). Specifically, the adaptor protein mAKAP mediates the binding of PKA and phosphodiesterase PDE43, whereas PP1 and PP2A are targeted to RyR2 via spinophilin and PR130,

respectively (Marx et al. 2000; Lehnart et al. 2005). All of the above mentioned proteins regulate the phosphorylation-dephosphorylation of RyR2 in Ser²⁸⁰⁸ (Shan et al. 2010) in response to stress (Andersson et al. 2011; Shan et al. 2010; Liu et al. 2012; Tester et al. 2007). Other channels are also regulated by stress signals including the voltage-gated Ca^{2+} channels (Maki et al. 1996). RyRs are also regulated by oxidation and nitrosylation (Shan et al. 2010; Andersson et al. 2011; Santulli 2017; Fauconnier et al. 2010). Other modulatory proteins complex directly and indirectly with RyR, including sorcin (Farrell et al. 2004), calmodulin (Meissner and Henderson 1987), homer (Feng et al. 2002), histidine-rich Ca^{2+} binding protein (Lee et al. 2001), triadin (Rossi et al. 2014), junctin (Zhang et al. 1997), and calsequestrin (Ohkura et al. 1998).

Intracellular Ca^{2+} leak

Ca^{2+} finely regulates innumerable events as muscle contraction, secretion, and gene transcription (Santulli and Marks 2015; Santulli 2017; Ringer 1883; Zetterstrom and Arnhold 1958; Jayaraman and Marks 2000). Cytosolic Ca^{2+} signals are produced by rapidly increasing the concentration of free Ca^{2+} ions (Blaustein 1993) by opening channels permeable to Ca^{2+} either in the surface cell membrane or in the membranes of intracellular organelles containing high Ca^{2+} concentrations. Amplification of external stimuli by triggering the release of intracellular Ca^{2+} stores represents a common signaling mechanism in the cell. The key role of RyRs in the rapid and voluminous release of Ca^{2+} from the SR during E–C coupling is well known. Importantly, RyRs are also crucially involved in maintaining Ca^{2+} homeostasis in the cell under resting conditions. Stress-induced remodeling of RyRs results in leaky channels and the inappropriate release of Ca^{2+} from the intracellular stores into the cytosol, contributing to the pathophysiology of diverse disorders including heart failure, cardiac arrhythmias, muscular dystrophy, diabetes, and cognitive dysfunction (Brillantes et al. 1994; Marx et al. 1998, 2000, 2001; Marks 2003; Reiken et al. 2003; Lehnart et al. 2005; Huang et al. 2006; Bellinger et al. 2008, 2009; Kushnir et al. 2010; Shan et al. 2010; Andersson et al. 2011, 2012; Santulli 2017; Marks et al. 2002; Liu et al. 2012; Tester et al. 2007; Fauconnier et al. 2010; Ward et al. 2003; Umanskaya et al. 2014; Matecki et al. 2016; Santulli et al. 2015a, 2015b; Xie et al. 2013, 2015).

Skeletal muscle

E–C coupling is similar in skeletal and cardiac muscle but there are important differences (Santulli 2017). Briefly, whereas in the heart a depolarizing Na^+ current activates Ca^{2+} influx via the L-type Ca^{2+} channel (LCC, $\text{Ca}_v1.2$),

206 which in turn activates the RyR2 isoform via Ca^{2+} -induced
 207 Ca^{2+} release (Fabiato and Fabiato 1975), the depolariza-
 208 tion of skeletal myocytes involves a protein–protein inter-
 209 action (Rios and Brum 1987) across the junctional cleft
 210 between the dihydropyridine receptor ($\text{Ca}_v1.1$) on special-
 211 ized invaginations of the sarcolemma (transverse tubules)
 212 and RyR1 on the SR membrane (terminal cisternae), lead-
 213 ing to Ca^{2+} release (Nelson et al. 2013). Both morphologic
 214 and electrophysiological data are consistent with the con-
 215 cept that four $\text{Ca}_v1.1$ s interact with a single RyR1 tetramer
 216 (one $\text{Ca}_v1.1$ binding to each RyR1 subunit). However, Fran-
 217 zini-Armstrong and Kish determined that a cluster of four
 218 $\text{Ca}_v1.1$ overlie only every other RyR1 tetramer (Franzini-
 219 Armstrong and Kish 1995). Reconciling those findings,
 220 we have demonstrated coupled gating of RyR1 (Marx et al.
 221 1998), which provides a mechanism by which RyR1 chan-
 222 nels that are not associated with $\text{Ca}_v1.1$ can be regulated.
 223 RyRs were initially observed in skeletal muscle, visualized
 224 in electron micrographs as large electron-dense masses
 225 located along the face of the SR terminal cisternae, which
 226 is closely apposed to transverse tubule membranes to form
 227 a structure named triad junction (Santulli 2017; Block et al.
 228 1988). Therefore, the RyRs were initially termed triad junc-
 229 tional foot proteins (Wagenknecht et al. 1989; Brandt et al.
 230 1990). Noda and colleagues provided the in vivo evidence
 231 for a functional role of RyR1 in E–C coupling, engineer-
 232 ing a mouse lacking exon 2 of *RyR1* and demonstrating that
 233 such a mouse exhibits severe skeletal muscle abnormalities
 234 and dies perinatally due to respiratory failure (Takeshima
 235 et al. 1994). Subsequent ultrastructural studies of hind
 236 limb and diaphragm muscles demonstrated the absence of
 237 RyR1- $\text{Ca}_v1.1$ complexes (Takekura et al. 1995), which are
 238 essential for a proper E–C coupling in the skeletal muscle
 239 (Nakai et al. 1996).

240 RyR1 dysfunction has been described in both inher-
 241 ited and acquired muscle disorders (Bellinger et al. 2008;
 242 Andersson et al. 2012). Central core disease (CCD) and
 243 malignant hyperthermia (MH) represent the best examples
 244 of RyR1 channelopathies in the skeletal muscle.

245 Central core disease (CCD)

246 CCD is a congenital myopathy first described in 1956
 247 (Magee and Shy 1956), characterized by the presence
 248 of tissue cores with reduced oxidative activity in type I
 249 myofibers, which results in progressive muscle weakness
 250 (Sewry et al. 2002). Common symptoms include hypoto-
 251 nia, delayed motor milestones, and skeletal abnormalities
 252 including congenital hip dislocation and scoliosis. Over 60
 253 different RyR1 mutations have been linked to CCD, which
 254 presents during infancy as delayed motor development
 255 and hypotonia. CCD occurs in 1:100,000 live births, and

comprises 16% of total congenital myopathies (Jungbluth 256
 2007). 257

258 We now know that RyR1 mutations cause the disorder
 259 which should be reclassified as RyR1 myopathies. There
 260 are no established therapeutics for RyR1 myopathies
 261 (Witherspoon and Meilleur 2016). The phenotypic presen-
 262 tation is quite variable ranging from near normal to neona-
 263 tal death. 263

264 The histopathological appearance of CCD is most
 265 closely linked to dominant RyR1 mutations (often mis-
 266 sense) clustered (Fig. 2) in disease causing “hot spots” in
 267 RyR1 (Quane et al. 1993; Zhang et al. 1993; Lynch et al.
 268 1999; Monnier et al. 2000; Scacheri et al. 2000), whereas
 269 RyR1 mutations (often truncating) causing recessive RyR1-
 270 related myopathies, including multi-minicore disease, cen-
 271 tronuclear myopathies, and congenital fiber-type dispro-
 272 portion, are evenly distributed throughout the entire RYR1
 273 coding sequence (Amburgey et al. 2013; Klein et al. 2012). 273

Malignant hyperthermia (MH) 274

275 MH is a pharmacogenetic disorder, inherited in an auto-
 276 somal dominant fashion and causes inhaled anesthetic-
 277 induced deaths in otherwise healthy individuals (Censier
 278 et al. 1998). MH episodes are typically rapid and severe,
 279 reaching core body temperatures of 43 °C, leading to organ
 280 failure and death if not rapidly treated. Susceptibility can be
 281 determined in vitro by measuring the contractile response
 282 to caffeine or halothane in biopsied muscle fibers. Over 100
 283 RyR1 mutations have been associated with MH, involving
 284 inappropriate activation of RyR1, which causes uncon-
 285 trolled release of SR Ca^{2+} and muscle contractions. MH
 286 occurs at a rate of 1:50,000–100,000 adults and 1:15,000
 287 children undergoing anesthesia; some studies have sug-
 288 gested a much more frequent rate of 1:5000 adults with MH
 289 susceptible mutations occurring at 1:3000 (Rosenberg et al.
 290 2007; Monnier et al. 2002). The exact prevalence of MH
 291 susceptibility is difficult to determine since the syndrome
 292 only becomes apparent after exposure to triggering agents
 293 including volatile anesthetic agents such as halothane, iso-
 294 flurane, sevoflurane, desflurane, enflurane and the neuro-
 295 muscular blocking agent succinylcholine (Larach 2007).
 296 A related syndrome referred to as porcine stress syndrome
 297 is found in certain lines of domestic swine where stressed
 298 pigs undergo stress-induced hyperthermia (Nelson and
 299 Bee 1979). Alterations in ^3H -ryanodine binding properties
 300 in porcine MH samples provided evidence linking RyR1
 301 dysfunction to the disease (Mickelson et al. 1988), which
 302 was later confirmed by biophysical experiments (Fill et al.
 303 1990). 303

304 Although dantrolene is an established therapeutic that
 305 quickly resolves MH episodes, mortality from this event
 306 remains at approximately 7% and a validated mechanism 306




Fig. 2 RyR1 with localization of the reported mutations for CCD (a–c) and MH (d–f). **a** and **d** are the full tetramer viewed top down from the cytosol, while **b** and **e** are rotated 90° to show the narrow transmembrane core and the larger cytoplasmic shell (an additional 45° rotation along the vertical axis was also performed). In **c**, **f** one

protomer is depicted (following a 60° rotation), demonstrating the high proportion of interprotomer mutation sites (in pink). Interestingly, CCD mutations typically occur in the pore forming C-terminal domain, while MH mutations occur in central and N-terminal clusters

of action for dantrolene has yet to be reported (Paul-Pletzer et al. 2002; Zhao et al. 2001). This remains a concern for otherwise healthy individuals harboring these mutations (Fill et al. 1990). Mutations causing MH are autosomal dominant and typically seen (Fig. 2) in the central and N-terminal clusters. Another MH mutation hotspot is at the inter-protomer contacts between the N-terminal domains A and B, which are disrupted in channel opening (Kimlicka et al. 2013).

Notably, there is no clear division between MH and RyR1 myopathies and some *RyR1* mutations have been linked to a combined MH and RyR1 myopathy phenotype (Zhou et al. 2007). Importantly, the mutated codons giving rise to MH and RyR1 myopathies tend to cluster in three specific regions of the *RyR1* gene (Fig. 2) corresponding to the following domains in the amino acid sequence: regions 1 (C35–R614) and 2 (D2129–R2458) reside in the myoplasmic foot domain of the protein, whereas region 3 (I3916–G4942) is located in the transmembrane/luminal region of the highly conserved carboxy-terminal domain, important for allowing Ca^{2+} flux through the channel (Zalk et al. 2015). Mutations in *RyR1* are also associated with other rare RyR1 related congenital myopathies including centronuclear myopathy, multi-minicore disease, Samaritan myopathy, heat/exercise induced exertional

rhabdomyolysis, congenital fiber-type disproportion, late-onset axial myopathy, and atypical periodic paralyses (Bharucha-Goebel et al. 2013; Zvaritch et al. 2009; Ferreira et al. 2002; Capacchione et al. 2010; Zhou et al. 2010; Inui et al. 1987; Takeshima et al. 1989; Loseth et al. 2013).

Intracellular Ca^{2+} leak and muscular dystrophy

We recently demonstrated that intracellular Ca^{2+} leak via RyR1 represents an essential feature of different forms of muscular dystrophy (MD), including Duchenne muscular dystrophy (Bellinger et al. 2009) and limb-girdle (or Erb's) MD (Andersson et al. 2012). Specifically, RyR1 from a Duchenne muscular dystrophy murine model (*mdx* mouse) was excessively cysteine nitrosylated and the RyR1 complex was depleted of calstabin1, leading to increased spontaneous RyR1 openings and reduced specific muscle force (Bellinger et al. 2009). Similar findings were obtained when evaluating RyR1 in β -sarcoglycan-deficient mice, an established model of limb-girdle muscular dystrophy (Andersson et al. 2012). Thus, we demonstrated common mechanisms of stress-induced remodeling of RyR1, including post-translational modifications of the channel and dissociation of the stabilizing subunit calstabin1, in two major disorders that weaken the muscular system hampering

locomotion and that remain without effective pharmacological treatment. We demonstrated in both cases that stabilizing the RyR1-calstabin1 association using a novel small molecule Rycal called S107 improved muscle function (Bellinger et al. 2009; Andersson et al. 2012), thereby providing an innovative therapeutic target and potential options for the treatment of muscular dystrophy.

In conditions of strenuous muscular stress or in a disease such as heart failure, both of which are characterized by chronic activation of the sympathetic nervous system and increased production of reactive oxygen and nitrogen species (Santulli 2014; Dalla Libera et al. 2005; Santulli and Iaccarino 2016), skeletal muscle function is impaired, possibly due to remodeling of RyR1 and impaired E–C coupling. We have shown in both an animal model as well as in exercising humans that chronic β AR stimulation and depletion of calstabin1 from RyR1 plays a role in contractile failure and muscle fatigue, defined as a decline in ability of a muscle to generate force during sustained exercise (Bellinger et al. 2008). Consistent with these observations, we have demonstrated that the remodeling of RyR1 plays a role in sarcopenia or age-dependent loss of muscle function (Andersson et al. 2011) and we were able to reduce RyR1 dysfunction and improve skeletal muscle function in aged mice (2 years old) by genetically enhancing mitochondrial antioxidant activity (Umanskaya et al. 2014).

Since skeletal muscle dysfunction, as observed in HF or muscular disorders, remains without effective treatment, drugs that restore RyR Ca^{2+} release function represent promising candidates. In this sense, Rycal treatment could be ideal in conditions that impair both cardiac and skeletal muscle function. Indeed, as well as muscular RyR1 undergoes post-translational modifications in HF (Reiken et al. 2003; Ward et al. 2003), remodeling of the cardiac RyR2 has been also reported in murine models of Duchenne muscular dystrophy, triggering ventricular arrhythmias (Fauconnier et al. 2010).

RyR1 mutations: clinical significance and structural effects

Over 300 mutations have been mapped to RyRs that are implicated in human diseases and 200 more that do not result in modified channel function. The disease causing mutations are most often found in hotspots, including the N-terminal (~1–600), the central (~2000–2600) and the C-terminal (~4000–5000) regions. High-resolution cryo-EM reconstructions have recently become available making it possible to see how these hotspots are localized, some in the channel pore and others in the inter-protomer and inter-domain interfaces (Tung et al. 2010). The phosphorylation domain is another hotspot for disease causing mutations (Yuchi et al. 2012).

Proper post-translational modifications and interaction with other proteins are also critical for RyR function. Several human disorders are linked to improper phosphorylation or oxidation of RyRs including ventilator-induced diaphragmatic dysfunction (VIDD) and Duchenne muscular dystrophy (DMD). VIDD involves diaphragm muscle weakness after extended mechanical ventilation and has been linked to oxidation of RyR (Matecki et al. 2016). RyR1 cysteine-nitrosylation has been shown to have a role in DMD (Bellinger et al. 2009). An age-dependent increase in cysteine-nitrosylation occurs with dystrophic changes in the muscle, depleting the RyR1 macromolecular complex of calstabin1 resulting in Ca^{2+} leak. This finding links muscle inflammation and Ca^{2+} leak in the pathogenesis of DMD (Tidball and Villalta 2009). Indeed, in inflamed tissues there is an increased expression of inducible nitric oxide synthase (iNOS), which binds to RyR1 leading to Ca^{2+} leak and eventually to the activation of Ca^{2+} -dependent proteases (calpains) that promote muscle damage and wasting.

These alterations affect the function of RyRs, but the direct impact on the tetrameric assembly has yet to be shown in structural studies. Due to the critical requirement of the channel for proper muscle function, mutations that severely destabilize or significantly alter the channel structure most likely lead to non-viable embryos. These mutations most often lead to changes in the open probability of the channel, leading to Ca^{2+} leak. This hypersensitive activation can come from mutations on either the luminal or the cytosolic side of the receptor (Tong et al. 1997; Jiang et al. 2004). One potential explanation is that defects at the interface between the central and N-terminal regions would weaken the interactions stabilizing the receptor in the closed state, leading to increased susceptibility to stimuli (Tateishi et al. 2009; Suetomi et al. 2011). Albeit many disease-associated RyR1 mutations do increase the open probability of the channel, this is far from certain for all RyR1 mutations, in particular with regards to recessive RyR1-related myopathies associated with reduction of the RyR1 protein. Therefore, compounds enhancing the closed probability of the channel would have limited application in conditions where the RyR1 mutations result in reduced rather than enhanced Ca^{2+} conductance, or where the precise functional consequences of the specific RyR1 mutations are not known.

Adjacent RyRs are known to signal cooperatively as paracrystalline arrays in checkerboard patterns, allowing for simultaneous opening of multiple channels (coupled gating) in response to a stimulus (Marx et al. 1998; Cabra et al. 2016). This provides a mechanism by which RyR channels can effect the rapid and coordinated SR Ca^{2+} release (via mechanically triggering neighboring channels) that is required for EC coupling. Thus, RyRs act as both

459 signal amplifiers and integrators by triggering neighboring
460 channels both physically and chemically with Ca^{2+} (Endo
461 et al. 1970; Fabiato 1983).

462 **Acknowledgements** The studies described in this review were
463 supported by NIH grants (R01AR060037 and R01HL061503)
464 and the Fondation Leducq to A.R.M. G.S. is supported by the NIH
465 (K99DK107895). ARM is a consultant and member of the board
466 of ARMGO Pharma that is targeting RyR channels for therapeutic
467 purposes.

468 References

469 Amburgey K et al (2013) Genotype-phenotype correlations in recessive RYR1-related myopathies. *Orphanet J Rare Dis* 8:117
470
471 Andersson DC et al (2011) Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. *Cell Metab* 14(2):196–207
472
473 Andersson DC et al (2012) Leaky ryanodine receptors in beta-sarcoglycan deficient mice: a potential common defect in muscular dystrophy. *Skelet Muscle* 2(1):9
474
475 Awad SS et al (1997) Differential expression of ryanodine receptor RyR2 mRNA in the non-pregnant and pregnant human myometrium. *Biochem J* 322(Pt 3):777–783
476
477 Bellinger AM, Mongillo M, Marks AR (2008a) Stressed out: the skeletal muscle ryanodine receptor as a target of stress. *J Clin Invest* 118(2):445–453
478
479 Bellinger AM et al (2008b) Remodeling of ryanodine receptor complex causes “leaky” channels: a molecular mechanism for decreased exercise capacity. *Proc Natl Acad Sci USA* 105(6):2198–2202
480
481 Bellinger AM et al (2009) Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. *Nat Med* 15(3):325–330
482
483 Bezprozvanny IB et al (1993) Activation of the calcium release channel (ryanodine receptor) by heparin and other polyanions is calcium dependent. *Mol Biol Cell* 4(3):347–352
484
485 Bharucha-Goebel DX et al (2013) Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrum. *Neurology* 80(17):1584–1589
486
487 Blaustein MP (1993) Physiological effects of endogenous ouabain: control of intracellular Ca^{2+} stores and cell responsiveness. *Am J Physiol* 264(6 Pt 1):C1367–C1387
488
489 Block BA et al (1988) Structural evidence for direct interaction between the molecular components of the transverse tubule/sarcoplasmic reticulum junction in skeletal muscle. *J Cell Biol* 107(6 Pt 2):2587–2600
490
491 Brandt NR et al (1990) Molecular interactions of the junctional foot protein and dihydropyridine receptor in skeletal muscle triads. *J Membr Biol* 113(3):237–251
492
493 Brillantes AB et al (1994) Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. *Cell* 77(4):513–523
494
495 Brochet DX et al (2005) Ca^{2+} blinks: rapid nanoscopic store calcium signaling. *Proc Natl Acad Sci USA* 102(8):3099–3104
496
497 Cabra V, Murayama T, Samsó M (2016) Ultrastructural analysis of self-associated RyR2s. *Biophys J* 110(12):2651–2662
498
499 Capacchione JF et al (2010) Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and calsequestrin-1 gene polymorphisms. *Anesthesiology* 112(1):239–244
500
501 Censier K et al (1998) Intracellular calcium homeostasis in human primary muscle cells from malignant

hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. *J Clin Invest* 101(6):1233–1242
519
520
521 Chen S, Novick P, Ferro-Novick S (2013) ER structure and function. *Curr Opin Cell Biol* 25(4):428–433
522
523 Copello JA et al (1997) Heterogeneity of Ca^{2+} gating of skeletal muscle and cardiac ryanodine receptors. *Biophys J* 73(1):141–156
524
525 Dalla Libera L et al (2005) Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. *J Mol Cell Cardiol* 38(5):803–807
526
527 des Georges A et al (2016) Structural basis for gating and activation of RyR1. *Cell* 167(1):145–157 e17
528
529 Endo M, Tanaka M, Ogawa Y (1970) Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. *Nature* 228(5266):34–36
530
531 Fabiato A (1983) Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. *Am J Physiol* 245(1):C1–C14
532
533 Fabiato A, Fabiato F (1975) Contractions induced by a calcium-triggered release of calcium from the sarcoplasmic reticulum of single skinned cardiac cells. *J Physiol* 249(3):469–495
534
535 Fairhurst AS, Hasselbach W (1970) Calcium efflux from a heavy sarcotubular fraction. Effects of ryanodine, caffeine and magnesium. *Eur J Biochem* 13(3):504–509
536
537 Farrell EF et al (2004) Regulation of cardiac excitation-contraction coupling by sorcin, a novel modulator of ryanodine receptors. *Biol Res* 37(4):609–612
538
539 Fauconnier J et al (2010) Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. *Proc Natl Acad Sci USA* 107(4):1559–1564
540
541 Feng W et al (2002) Homer regulates gain of ryanodine receptor type 1 channel complex. *J Biol Chem* 277(47):44722–44730
542
543 Ferreira A et al (2002) A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. *Ann Neurol* 51(6):750–759
544
545 Fill M et al (1990a) Abnormal ryanodine receptor channels in malignant hyperthermia. *Biophys J* 57(3):471–475
546
547 Fill M et al (1990b) Abnormal ryanodine receptor channels in malignant hyperthermia. *Biophys J* 57(3):471–475
548
549 Flucher BE et al (1993) Triad formation: organization and function of the sarcoplasmic reticulum calcium release channel and triadin in normal and dysgenic muscle in vitro. *J Cell Biol* 123(5):1161–1174
550
551 Franzini-Armstrong C, Kish JW (1995) Alternate disposition of tetrads in peripheral couplings of skeletal muscle. *J Muscle Res Cell Motil* 16(3):319–324
552
553 Go LO et al (1995) Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. *J Clin Invest* 95(2):888–894
554
555 Gordon AM, Homsher E, Regnier M (2000) Regulation of contraction in striated muscle. *Physiol Rev* 80(2):853–924
556
557 Huang F et al (2006) Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice. *Proc Natl Acad Sci USA* 103(9):3456–3461
558
559 Hwang JH et al (2012) Mapping domains and mutations on the skeletal muscle ryanodine receptor channel. *Trends Mol Med* 18(11):644–657
560
561 Inui M, Saito A, Fleischer S (1987) Purification of the ryanodine receptor and identity with feet structures of junctional terminal cisternae of sarcoplasmic reticulum from fast skeletal muscle. *J Biol Chem* 262(4):1740–1747
562
563 Jayaraman T et al (1992) FK506 binding protein associated with the calcium release channel (ryanodine receptor). *J Biol Chem* 267(14):9474–9477
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583

- 584 Jayaraman T, Marks AR (2000) Calcineurin is downstream of the
585 inositol 1,4,5-trisphosphate receptor in the apoptotic and cell
586 growth pathways. *J Biol Chem* 275(9):6417–6420
- 587 Jiang D et al (2004) RyR2 mutations linked to ventricular tachycar-
588 dia and sudden death reduce the threshold for store-overload-
589 induced Ca²⁺ release (SOICR). *Proc Natl Acad Sci USA*
590 101(35):13062–13067
- 591 Jungbluth H (2007) Central core disease. *Orphanet J Rare Dis* 2:25
- 592 Kimlicka L et al (2013) Disease mutations in the ryanodine receptor
593 N-terminal region couple to a mobile intersubunit interface. *Nat*
594 *Commun* 4:1506
- 595 Klein A et al (2012) Clinical and genetic findings in a large cohort of
596 patients with ryanodine receptor 1 gene-associated myopathies.
597 *Hum Mutat* 33(6):981–988
- 598 Kushnir A et al (2010) Role of CaMKII δ phosphorylation
599 of the cardiac ryanodine receptor in the force frequency
600 relationship and heart failure. *Proc Natl Acad Sci USA*
601 107(22):10274–10279
- 602 Lanner JT et al (2010) Ryanodine receptors: structure, expression,
603 molecular details, and function in calcium release. *Cold Spring*
604 *Harb Perspect Biol* 2(11):a003996
- 605 Larach MG et al (2014) Malignant hyperthermia deaths related to
606 inadequate temperature monitoring, 2007–2012: a report from
607 The North American Malignant Hyperthermia Registry of the
608 Malignant Hyperthermia Association of the United States.
609 *Anesth Analg*
- 610 Laver DR et al (1995) Cytoplasmic Ca²⁺ inhibits the ryanodine
611 receptor from cardiac muscle. *J Membr Biol* 147(1):7–22
- 612 Lee HG et al (2001) Interaction of HRC (histidine-rich Ca(2+)-bind-
613 ing protein) and triadin in the lumen of sarcoplasmic reticulum.
614 *J Biol Chem* 276(43):39533–39538
- 615 Lehnart SE et al (2005) Phosphodiesterase 4D deficiency in the ryan-
616 odine-receptor complex promotes heart failure and arrhythmias.
617 *Cell* 123(1):25–35
- 618 Liu X et al (2012) Role of leaky neuronal ryanodine receptors in
619 stress-induced cognitive dysfunction. *Cell* 150(5):1055–1067
- 620 Loseth S et al (2013) A novel late-onset axial myopathy associ-
621 ated with mutations in the skeletal muscle ryanodine receptor
622 (RYR1) gene. *J Neurol* 260(6):1504–1510
- 623 Lynch PJ et al (1999) A mutation in the transmembrane/luminal
624 domain of the ryanodine receptor is associated with abnormal
625 Ca²⁺ release channel function and severe central core disease.
626 *Proc Natl Acad Sci USA* 96(7):4164–4169
- 627 Magee KR, Shy GM (1956) A new congenital non-progressive myo-
628 pathy. *Brain* 79(4):610–621
- 629 Maki T et al (1996) Regulation of calcium channel expression in neo-
630 natal myocytes by catecholamines. *J Clin Invest* 97(3):656–663
- 631 Marks AR et al (1989) Molecular cloning and characterization of the
632 ryanodine receptor/junctional channel complex cDNA from
633 skeletal muscle sarcoplasmic reticulum. *Proc Natl Acad Sci*
634 *USA* 86(22):8683–8687
- 635 Marks AR et al (1990) Smooth muscle and brain inositol 1,4,5-tris-
636 phosphate receptors are structurally and functionally similar. *J*
637 *Biol Chem* 265(34):20719–20722
- 638 Marks AR et al (2002) Involvement of the cardiac ryanodine receptor/
639 calcium release channel in catecholaminergic polymorphic ven-
640 tricular tachycardia. *J Cell Physiol* 190(1):1–6
- 641 Marks AR (2003) A guide for the perplexed: towards an under-
642 standing of the molecular basis of heart failure. *Circulation*
643 107(11):1456–1459
- 644 Marx SO et al (2000) PKA phosphorylation dissociates FKBP12.6
645 from the calcium release channel (ryanodine receptor): defect-
646 ive regulation in failing hearts. *Cell* 101(4):365–376
- 647 Marx SO et al (2001) Phosphorylation-dependent regulation of ryan-
648 odine receptors: a novel role for leucine/isoleucine zippers. *J Cell*
649 *Biol* 153(4):699–708
- Marx SO, Ondrias K, Marks AR (1998) Coupled gating between
individual skeletal muscle Ca²⁺ release channels (ryanodine
receptors). *Science* 281(5378):818–821
- Matecki S et al (2016) Leaky ryanodine receptors contribute to
diaphragmatic weakness during mechanical ventilation. *Proc*
Natl Acad Sci 113(32):9069–9074
- Meissner G, Henderson JS (1987) Rapid calcium release from car-
diac sarcoplasmic reticulum vesicles is dependent on Ca²⁺
and is modulated by Mg²⁺, adenine nucleotide, and calmodu-
lin. *J Biol Chem* 262(7):3065–3073
- Mickelson JR et al (1988) Abnormal sarcoplasmic reticulum
ryanodine receptor in malignant hyperthermia. *J Biol Chem*
263(19):9310–9315
- Monnier N et al (2000) An autosomal dominant congenital myopa-
thy with cores and rods is associated with a neomutation in
the RYR1 gene encoding the skeletal muscle ryanodine recep-
tor. *Hum Mol Genet* 9(18):2599–2608
- Monnier N et al (2002) Presence of two different genetic traits in
malignant hyperthermia families: implication for genetic
analysis, diagnosis, and incidence of malignant hyperthermia
susceptibility. *Anesthesiology* 97(5):1067–1074
- Nakai J et al (1996) Enhanced dihydropyridine receptor chan-
nel activity in the presence of ryanodine receptor. *Nature*
380(6569):72–75
- Nakashima Y et al (1997) Molecular cloning and characterization of
a human brain ryanodine receptor. *FEBS Lett* 417(1):157–162
- Nelson BR et al (2013) Skeletal muscle-specific T-tubule protein
STAC3 mediates voltage-induced Ca²⁺ release and contrac-
tility. *Proc Natl Acad Sci USA* 110(29):11881–11886
- Nelson TE, Bee DE (1979) Temperature perturbation studies of sar-
coplasmic reticulum from malignant hyperthermia pig mus-
cle. *J Clin Invest* 64(4):895–901
- Ohkura M et al (1998) Dual regulation of the skeletal muscle ryan-
odine receptor by triadin and calsequestrin. *Biochemistry*
37(37):12987–12993
- Otsu K et al (1990) Molecular cloning of cDNA encoding the Ca²⁺-
release channel (ryanodine receptor) of rabbit cardiac muscle
sarcoplasmic reticulum. *J Biol Chem* 265(23):13472–13483
- Paul-Pletzer K et al (2002) Identification of a dantrolene-binding
sequence on the skeletal muscle ryanodine receptor. *J Biol*
Chem 277(38):34918–34923
- Quane KA et al (1993) Mutations in the ryanodine receptor gene in
central core disease and malignant hyperthermia. *Nat Genet*
5(1):51–55
- Reiken S et al (2003) PKA phosphorylation activates the calcium
release channel (ryanodine receptor) in skeletal muscle: defect-
ive regulation in heart failure. *J Cell Biol* 160(6):919–928
- Ringer S (1883) A further Contribution regarding the influence of
the different constituents of the blood on the contraction of
the heart. *J Physiol* 4(1):29–42.3
- Rios E, Brum G (1987) Involvement of dihydropyridine receptors
in excitation–contraction coupling in skeletal muscle. *Nature*
325(6106):717–720
- Rogers EF, Koniuszy FR et al (1948) Plant insecticides; ryanodine,
a new alkaloid from *Ryania speciosa* Vahl. *J Am Chem Soc*
70(9):3086–3088
- Rosenberg H et al (2007) Malignant hyperthermia. *Orphanet J Rare*
Dis 2:21
- Rossi D et al (2014) Distinct regions of triadin are required for tar-
geting and retention at the junctional domain of the sarcoplas-
mic reticulum. *Biochem J* 458(2):407–417
- Santulli G (2014) Adrenal signaling in heart failure: something
more than a distant ship's smoke on the horizon. *Hyperten-
sion* 63(2):215–216

- 714 Santulli G et al (2015a) Calcium release channel RyR2 regu- 775
 715 lates insulin release and glucose homeostasis. *J Clin Invest* 776
 716 125(5):1968–1978 777
 717 Santulli G et al (2015b) Mitochondrial calcium overload is a 778
 718 key determinant in heart failure. *Proc Natl Acad Sci USA* 779
 719 112(36):11389–11394 780
 720 Santulli G, Iaccarino G (2016) Adrenergic signaling in heart failure 781
 721 and cardiovascular aging. *Maturitas* 93:65–72 782
 722 Santulli G, Marks AR (2015) Essential roles of intracellular calcium 783
 723 release channels in muscle, brain, metabolism, and aging. *Curr* 784
 724 *Mol Pharmacol* 8(2):206–222 785
 725 Santulli G et al. (2017) Intracellular calcium release channels: an 786
 726 update. *J Physiol* 787
 727 Scacheri PC et al (2000) A novel ryanodine receptor gene mutation 788
 728 causing both cores and rods in congenital myopathy. *Neurology* 789
 729 55(11):1689–1696 790
 730 Sewry CA et al (2002) The spectrum of pathology in central core dis- 791
 731 ease. *Neuromuscul Disord* 12(10):930–938 792
 732 Shan J et al (2010) Role of chronic ryanodine receptor phosphoryla- 793
 733 tion in heart failure and beta-adrenergic receptor blockade in 794
 734 mice. *J Clin Invest* 120(12):4375–4387 795
 735 Shan J et al (2010) Phosphorylation of the ryanodine receptor medi- 796
 736 ates the cardiac fight or flight response in mice. *J Clin Invest* 797
 737 120(12):4388–4398 798
 738 Suetomi T et al (2011) Mutation-linked defective interdomain interac- 799
 739 tions within ryanodine receptor cause aberrant Ca²⁺(+)-release 800
 740 leading to catecholaminergic polymorphic ventricular tachycar- 801
 741 dia. *Circulation* 124(6):682–694 802
 742 Takekura H et al (1995) Abnormal junctions between surface mem- 803
 743 brane and sarcoplasmic reticulum in skeletal muscle with a 804
 744 mutation targeted to the ryanodine receptor. *Proc Natl Acad Sci* 805
 745 *USA* 92(8):3381–3385 806
 746 Takeshima H et al (1989) Primary structure and expression from com- 807
 747plementary DNA of skeletal muscle ryanodine receptor. *Nature* 808
 748 339(6224):439–445 809
 749 Takeshima H et al (1994) Excitation–contraction uncoupling and 810
 750 muscular degeneration in mice lacking functional skeletal mus- 811
 751 cle ryanodine-receptor gene. *Nature* 369(6481):556–559 812
 752 Tateishi H et al (2009) Defective domain–domain interactions within 813
 753 the ryanodine receptor as a critical cause of diastolic Ca²⁺ leak 814
 754 in failing hearts. *Cardiovasc Res* 81(3):536–545 815
 755 Tester DJ et al (2007) A mechanism for sudden infant death syndrome 816
 756 (SIDS): stress-induced leak via ryanodine receptors. *Heart* 817
 757 *Rhythm* 4(6):733–739 818
 758 Tidball JG, Villalta SA (2009) NO may prompt calcium leakage in 819
 759 dystrophic muscle. *Nat Med* 15(3):243–244 820
 760 Timerman AP et al (1993) The calcium release channel of sarcoplas- 821
 761 mic reticulum is modulated by FK-506-binding protein. Dis- 822
 762 sociation and reconstitution of FKBP-12 to the calcium release 823
 763 channel of skeletal muscle sarcoplasmic reticulum. *J Biol Chem* 824
 764 268(31):22992–22999 825
 765 Tobacman LS (1996) Thin filament-mediated regulation of cardiac 826
 766 contraction. *Annu Rev Physiol* 58:447–481 827
 767 Tong J et al (1997) Caffeine and halothane sensitivity of intracel- 828
 768 lular Ca²⁺ release is altered by 15 calcium release chan- 829
 769 nel (ryanodine receptor) mutations associated with malign- 830
 770 ant hyperthermia and/or central core disease. *J Biol Chem* 831
 771 272(42):26332–26339 832
 772 Tung CC et al (2010) The amino-terminal disease hotspot of 833
 773 ryanodine receptors forms a cytoplasmic vestibule. *Nature*
 774 468(7323):585–588
- Umanskaya A et al (2014) Genetically enhancing mitochondrial anti- 775
 oxidant activity improves muscle function in aging. *Proc Natl* 776
 Acad Sci USA 111(42):15250–15255 777
 Wagenknecht T et al (1989) Three-dimensional architecture of the 778
 calcium channel/foot structure of sarcoplasmic reticulum. 779
Nature 338(6211):167–170 780
 Ward CW et al (2003) Defects in ryanodine receptor calcium release 781
 in skeletal muscle from post-myocardial infarct rats. *FASEB J* 782
 17(11):1517–1519 783
 Witherspoon JW, Meilleur KG (2016) Review of RyR1 pathway 784
 and associated pathomechanisms. *Acta Neuropathol Commun* 785
 4(1):121 786
 Xie W et al (2013) Imaging atrial arrhythmic intracellular calcium in 787
 intact heart. *J Mol Cell Cardiol* 64:120–123 788
 Xie W et al (2015) Mitochondrial oxidative stress promotes atrial 789
 fibrillation. *Sci Rep* 5:11427 790
 Xin HB et al (1995) Affinity purification of the ryanodine receptor/ 791
 calcium release channel from fast twitch skeletal muscle based 792
 on its tight association with FKBP12. *Biochem Biophys Res* 793
 Commun 214(1):263–270 794
 Yan Z et al (2015) Structure of the rabbit ryanodine receptor RyR1 at 795
 near-atomic resolution. *Nature* 517(7532):50–55 796
 Yuan Q et al (2014) Functional role of calstabin2 in age-related car- 797
 diac alterations. *Sci Rep* 4:7425 798
 Yuan Q et al (2016) Maintenance of normal blood pressure is depend- 799
 ent on IP3R1-mediated regulation of eNOS. *Proc Natl Acad Sci* 800
 USA 113(30):8532–8537 801
 Yuchi Z, Lau K, Van Petegem F (2012) Disease mutations in the ryan- 802
 odine receptor central region: crystal structures of a phospho- 803
 rylation hot spot domain. *Structure* 20(7):1201–1211 804
 Zalk R et al (2015) Structure of a mammalian ryanodine receptor. 805
Nature 517(7532):44–49 806
 Zetterstrom R, Arnhold RG (1958) Impaired calcium-phosphate 807
 homeostasis in newborn infants of diabetic mothers. *Acta Pae- 808
 diatr* 47(2):107–112 809
 Zhang Y et al (1993) A mutation in the human ryanodine receptor 810
 gene associated with central core disease. *Nat Genet* 5(1):46–50 811
 Zhang L et al (1997) Complex formation between junctin, triadin, 812
 calsequestrin, and the ryanodine receptor. Proteins of the car- 813
 diac junctional sarcoplasmic reticulum membrane. *J Biol Chem* 814
 272(37):23389–23397 815
 Zhang L et al (2011) Functional SNP in the microRNA-367 binding 816
 site in the 3'UTR of the calcium channel ryanodine receptor 817
 gene 3 (RYR3) affects breast cancer risk and calcification. *Proc* 818
 Natl Acad Sci USA 108(33):13653–13658 819
 Zhao F et al (2001) Dantrolene inhibition of ryanodine receptor Ca²⁺- 820
 release channels. Molecular mechanism and isoform selectivity. 821
J Biol Chem 276(17):13810–13816 822
 Zhou H et al (2007) Molecular mechanisms and phenotypic vari- 823
 ation in RYR1-related congenital myopathies. *Brain* 130(Pt 824
 8):2024–2036 825
 Zhou H et al (2010) Multi-minicore disease and atypical periodic 826
 paralysis associated with novel mutations in the skeletal mus- 827
 cle ryanodine receptor (RYR1) gene. *Neuromusc Disord NMD* 828
 20(3):166–173 829
 Zvaritch E et al (2009) Ca²⁺ dysregulation in Ryr1(I4895T/wt) mice 830
 causes congenital myopathy with progressive formation of 831
 minicores, cores, and nemaline rods. *Proc Natl Acad Sci USA* 832
 106(51):21813–21818 833